{
    "Trade/Device Name(s)": [
        "D-10 Hemoglobin A1c Program",
        "D-10 Hemoglobin Testing System"
    ],
    "Submitter Information": "Bio-Rad Laboratories, Inc.",
    "510(k) Number": "K161687",
    "Predicate Device Reference 510(k) Number(s)": [
        "K142448"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PDJ"
    ],
    "Summary Letter Date": "August 30, 2016",
    "Summary Letter Received Date": "September 1, 2016",
    "Submission Date": "October 12, 2016",
    "Regulation Number(s)": [
        "21 CFR 862.1373"
    ],
    "Regulation Name(s)": [
        "Glycosylated hemoglobin assay"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Hemoglobin A1c"
    ],
    "Specimen Type(s)": [
        "Whole Blood"
    ],
    "Specimen Container(s)": [
        "K2-EDTA tube",
        "K3-EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "D-10 Hemoglobin Testing System"
    ],
    "Method(s)/Technology(ies)": [
        "Ion-exchange high-performance liquid chromatography (HPLC)"
    ],
    "Methodologies": [
        "Chromatographic separation",
        "Photometric detection",
        "Calibration against reference standards"
    ],
    "Submission Type(s)": [
        "Assay",
        "Analyzer",
        "Reagent",
        "Calibrator",
        "Cartridge",
        "Buffer",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for D-10 Hemoglobin A1c Program assay using ion-exchange HPLC on the D-10 Hemoglobin Testing System for quantitative HbA1c measurement",
    "Indications for Use Summary": "Quantitative determination of hemoglobin A1c in human whole blood as an aid in diagnosis of diabetes, identification of patients at risk for developing diabetes mellitus, and monitoring long-term blood glucose control in individuals with diabetes mellitus",
    "fda_folder": "Clinical Chemistry"
}